enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances ...
(PR-inside.com) Company Enters the Second Half of 2026 With Tailwinds From an FDA IDE Approval, With the TAVVE Pivotal Study Expected to Begin Enrolling Patients During the Second Half of This Year and Cash Runway Extending Into the Third Quarter of 2027 IRVINE, CA / ACCESS Newswire / July 31, 2026 / enVVeno Medical Co…
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


